BioAge Q2 FY26 net loss widens to $26.1 million; R&D expenses rise to $24.37 million
BIOA•Clinical program updates
- The first participant was dosed in QUELL-CV Phase 2; topline data are expected in H2 2026, with QUELL-DME planned for mid-2026.
Quarterly results and expenses
- BioAge Labs posted a Q2 net loss of $26.1 million, worsening from $21.6 million a year earlier.
- R&D expenses rose to $24.4 million, up from $19.8 million, on higher BGE-102 costs tied to QUELL-CV initiation.
- Collaboration revenue was $2.4 million, in line with the year-earlier quarter.
- Cash, cash equivalents, and marketable securities totaled $381.3 million as of June 30, with runway expected through 2029.
Related News
Airbnb Chief Strategy Officer Nathan Blecharczyk disposes of 17,692 shares worth $2.67 million
ABNB•
UMH Properties Q2 FY26 net income attributable to common shareholders rises 75% to $4.42 million; revenue climbs 9% to $61.09 million
UMH•
